Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company based in San Francisco, is focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain. The stock is down by about 20% over the last month and by almost 50% in the last quarter.

How Bempegaldesleukin Woes Have Impacted Nektar Therapeutics

Nektar (NKTR) continues its downfall in 2019. Goldman Sachs downgrades the company's rating from Buy to Sell.

Nektar's Shares Drop on Rating Downgrade by Goldman Sachs

Autolus Therapeutics

Mirati Therapeutics

Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.

3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting

Nektar Therapeutics (NASDAQ: NKTR) has seen several setbacks in the near-term, including sagging revenues and a regulatory delay for its investigational opioid analgesic.

Nektar Hit With Double Downgrade From Goldman: 'Significant Challenges In Rebuilding Confidence'

An analyst downgrade is only adding to the company's woes.

Here's Why Nektar Therapeutics Stock Fell as Much as 11.6% Today

Nektar Therapeutics shares NKTR, -1.56% slid 6.3% in premarket trade Tuesday, after Goldman Sachs downgraded the stock to sell from buy and said the stock will likely flounder in the near term due to quality issues and a narrower focus for bempegaldesleukin, its treatment for cancer.

Nektar Therapeutics shares slide 6.3% premarket after Goldman downgrades to sell from buy

Nektar Therapeutics (NKTR) presents preliminary data on triple negative breast cancer patients from an early-stage study, which fails to impress investors.

Nektar Stock Down on Disappointing Breast Cancer Study Data

Nektar shares have been hammered on manufacturing issues with its lead drug and a significantly smaller number of registration studies with partner Bristol-Myers.

Nektar Hammered On Multiple Setbacks; Core Efficacy Questions Remain Open

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

Why Is Nektar (NKTR) Down 42.5% Since Last Earnings Report?

Align Technology

Cabot Oil & Gas

The market whipsawed over the past three months as major macroeconomic events, from tariff battles to yield-curve inversions, bombarded investors.

Stocks the Market Is Discounting the Most This Summer

Manufacturing issues plague the start-up.

Here's Why Nektar Therapeutics Plummeted 38% in August

The biotech continues to feel the repercussions from news announced last week.

Why Nektar Therapeutics Stock Is Falling Again Today

Farfetch

Waitr Holdings Inc

Find out why these stocks stood out on a down day for the markets.

Why Farfetch, Waitr Holdings, and Nektar Therapeutics Slumped Today

Nektar Therapeutics (NASDAQ: NKTR) crashed more than 30% Friday after the company reported a huge second-quarter sales miss.

Large Option Trader Buying Nektar Calls Following Stock Crash

Nektar Therapeutics stock crashed to a two-year low Friday after the biotech company revealed a manufacturing issue could have skewed the results of several cancer treatment studies.
The post Biotech Crashes 35% After Bad Drug Likely Skewed Cancer Drug Tests appeared first on Investor's Business Daily.

Biotech Crashes 35% After Bad Drug Likely Skewed Cancer Drug Tests

Nektar's (NKTR) reports narrower-than expected loss in the second quarter but stock declines.

Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss

Nektar Therapeutics (NASDAQ: NKTR) shares were plummeting to a two-year low Friday following the release of its quarterly results the prior afternoon, wiping away roughly $1.9 billion of its market value.

Nektar Therapeutics Tumbles To 2-Year Low On Q2 Revenue Miss, Manufacturing Issues With Cancer Drug

The biotech's Q2 numbers weren't nearly as sweet as they were a year ago. But the main focus continues to be on its pipeline progress.

What You'll Want to Know About Nektar Therapeutics' Q2 Results

Nektar Therapeutics' (NKTR) CEO Howard Robin on Q2 2019 Results - Earnings Call Transcript

Nektar Therapeutics NKTR, +2.67% shares dropped in the extended session Thursday after the biotech company's revenue came in below Wall Street targets.

Nektar Therapeutics stock drops after results

Nektar (NKTR) delivered earnings and revenue surprises of 21.25% and -10.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

Nektar Therapeutics stock was halted late Thursday ahead of the biotech company's second-quarter earnings announcement. Nektar stock closed up 2.7% during the regular trading session.

Another Biotech Stock Halted As Quarterly Sales Lag Forecasts

Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Nektar (NKTR) Ahead of Earnings?

The company can't seem to sustain any momentum.

Here's Why Nektar Therapeutics Declined 20% in July

The focus will be on Nektar Therapeutics' (NKTR) pipeline progress and launch plans for NKTR-181 when the company reports second-quarter results.

News for Nektar Therapeutics Stock (NKTR)